Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Shattuck Labs, Inc.NASDAQ: STTK

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$891K, compared with -$936K a year earlier. Trailing-twelve-month gross profit was -$820K.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, up 85.5 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$891K or moves back toward the trailing-twelve-month quarterly average of -$205K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$891K— QoQ
Last fiscal yearDec 2025
$1M+20.9% YoY
LTMMar 2026
-$820K-146.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.8%——
1 year+20.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
1M USD
Year-over-year change
+20.9%
4-year CAGR
-56.8%

Gross Profit vs competitors

How STTK compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -146.7% is the 6th highest of 7, against a peer median of +50.2%.
  • Gross profit amounts to 82.0% of revenue for STTK, versus a peer median of 74.5%.
STTK Competitors
Gross Profit for STTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$201.75M USD+169.7%—53.2%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$169.15M USD+0.4%-0.5%74.5%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$11.88M USD—+424.9%100.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD———
PDSBPDS Biotechnology CorporationLTM Mar 2026$0 USD+100.0%——
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY+100.0%——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026-$113K USD-100.2%——
STTKShattuck Labs, Inc.LTM Mar 2026-$820K USD-146.7%—82.0%
FTHFaeth Therapeutics, Inc.LTM Jun 2026-$132.96M USD-47554.8%——
Peer median (excluding STTK) —+50.2%+212.2%74.5%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.02M652K1.66M5.72M1M
Cost of Revenue1.38M82.2M4.04M4.89M0
Gross Profit28.64M(81.55M)(2.39M)827K1M
Gross Margin95.4%-12507.2%-143.9%14.5%100.0%
Research & Development56.56M82.9M74.31M67.21M35.27M
Selling, General & Admin18.72M19.68M19.3M19.08M17.24M
Operating Expenses73.91M21.78M89.57M81.39M52.51M
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
EBITDA(43.59M)(98.87M)(83.26M)(71.58M)(45.12M)
EBITDA Margin-145.2%-15164.4%-5024.5%-1251.2%-4512.1%
Operating Income(45.27M)(103.33M)(91.96M)(80.57M)(51.51M)
Operating Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%
Interest Income625K1.59M4.67M5.17M2.7M
Interest Expense00000
Other Income / Expenses295K1.38M4.66M5.16M2.7M
Income Before Tax(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Pre-Tax Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
Income Tax Expense00000
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Net Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
EPS (Basic)(1.07)(2.41)(2.05)(1.49)(0.70)
EPS (Diluted)(1.07)(2.41)(2.05)(1.49)(0.70)
Weighted Avg Shares42.03M42.38M42.6M50.76M69.58M
Weighted Avg Shares (Diluted)42.03M42.38M42.6M50.76M69.58M

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.